Abstract | BACKGROUND: METHODS: A retrospective study of a prospective database revealed 89 patients with PC from appendiceal cancer who underwent 127 CRS/HIPECs. Surgical specimens from 59 patients were tested to identify high vs. low VEGFR-2 expression. Patient outcomes and survival were analyzed. RESULTS: There were 26 males and 33 females. Mean age was 51 years. Forty-seven VEGFR-2 high expressers and 15 low expressers were identified. Mean follow-up of high and low expressers was 25.1 and 26.6 months, respectively (p = 0.806). At follow-up, 33 (70%) high expressers were alive and 14 (30%) deceased, while 11 (92%) low expressers were alive and 1 (8%) deceased. Recurrence, use of bevacizumab, CC score, PCI, and LN status showed no differences between high and low expressers. OS for high expressers was 90.5%, 59.8%, and 47.1% at 1-, 3-, and 5-years, respectively, while OS for low expressers remained stable at 91.7% at 1-, 3-, and 5-years (p = 0.133). CONCLUSION: There is a trend towards better outcomes and survival in patients with PC from appendiceal cancer who have low expression of VEGFR-2 compared to high expression. More studies are encouraged to confirm this trend.
|
Authors | W A Jimenez, A Sardi, P Ledakis, C Nieroda, M Sittig, V Gushchin |
Journal | European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
(Eur J Surg Oncol)
Vol. 39
Issue 12
Pg. 1415-22
(Dec 2013)
ISSN: 1532-2157 [Electronic] England |
PMID | 24075030
(Publication Type: Journal Article)
|
Copyright | Copyright © 2013 Elsevier Ltd. All rights reserved. |
Chemical References |
- Antibodies, Monoclonal, Humanized
- Antineoplastic Agents
- RNA, Messenger
- RNA, Neoplasm
- Bevacizumab
- Vascular Endothelial Growth Factor Receptor-2
|
Topics |
- Adenocarcinoma
(genetics, secondary, therapy)
- Adult
- Aged
- Antibodies, Monoclonal, Humanized
(therapeutic use)
- Antineoplastic Agents
(administration & dosage)
- Appendiceal Neoplasms
(pathology)
- Bevacizumab
- Chemotherapy, Adjuvant
- Chemotherapy, Cancer, Regional Perfusion
- Female
- Gene Expression
- Humans
- Hyperthermia, Induced
- Kaplan-Meier Estimate
- Male
- Middle Aged
- Peritoneal Neoplasms
(genetics, secondary, therapy)
- Prognosis
- RNA, Messenger
(analysis)
- RNA, Neoplasm
(analysis)
- Retrospective Studies
- Survival Rate
- Vascular Endothelial Growth Factor Receptor-2
(genetics)
|